Actuate Therapeutics, Inc. (NASDAQ:ACTU) Short Interest Update

Actuate Therapeutics, Inc. (NASDAQ:ACTU) saw a significant growth in short interest during the month of August. As of August 14th, there was short interest totaling 695,971 shares, a growth of 54.6% from the July 30th total of 450,180 shares. Approximately 6.9% of the shares of the company are short sold. Based on an average daily volume of 193,080 shares, the days-to-cover ratio is presently 3.6 days.

Actuate Therapeutics Stock Down 4.2%

Shares of NASDAQ:ACTU traded down $0.06 during mid-day trading on Tuesday, reaching $1.46. 16,968 shares of the stock were exchanged, compared to its average volume of 201,355. The stock’s 50 day simple moving average is $1.35 and its 200-day simple moving average is $2.21. Actuate Therapeutics has a one year low of $0.90 and a one year high of $9.22. The company has a market cap of $34.96 million, a P/E ratio of -1.67 and a beta of 0.78.

Actuate Therapeutics (NASDAQ:ACTU) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. Analysts anticipate that Actuate Therapeutics will post -0.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. HC Wainwright reissued a “buy” rating on shares of Actuate Therapeutics in a report on Tuesday, August 18th. Wall Street Zen lowered shares of Actuate Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Wednesday, June 24th. Finally, Rodman & Renshaw initiated coverage on shares of Actuate Therapeutics in a research report on Thursday, July 30th. They issued a “buy” rating and a $6.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.50.

Hedge Funds Weigh In On Actuate Therapeutics

Hedge funds have recently made changes to their positions in the business. Voss Capital LP boosted its holdings in Actuate Therapeutics by 45.0% in the fourth quarter. Voss Capital LP now owns 1,300,000 shares of the company’s stock valued at $7,956,000 after purchasing an additional 403,722 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc purchased a new position in Actuate Therapeutics during the 2nd quarter valued at about $157,000. Palogic Value Management L.P. purchased a new stake in Actuate Therapeutics during the 2nd quarter worth about $153,000. BlackRock Inc. acquired a new position in shares of Actuate Therapeutics in the second quarter valued at approximately $138,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Actuate Therapeutics by 252.5% during the second quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock worth $721,000 after purchasing an additional 84,561 shares during the last quarter.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.